These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19155012)

  • 1. Iron, metabolic syndrome, nonalcoholic fatty liver disease and carotid atherosclerosis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Atherosclerosis; 2009 Jul; 205(1):39-40. PubMed ID: 19155012
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome.
    Zimmermann A; Zimmermann T; Schattenberg J; Pöttgen S; Lotz J; Rossmann H; Roeddiger R; Biesterfeld S; Geiss HC; Schuchmann M; Galle PR; Weber MM
    Eur J Intern Med; 2011 Jun; 22(3):305-10. PubMed ID: 21570653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.
    Valenti L; Fracanzani AL; Dongiovanni P; Bugianesi E; Marchesini G; Manzini P; Vanni E; Fargion S
    Am J Gastroenterol; 2007 Jun; 102(6):1251-8. PubMed ID: 17391316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease].
    Kim MY; Baik SK
    Korean J Hepatol; 2008 Mar; 14(1):1-3. PubMed ID: 18367852
    [No Abstract]   [Full Text] [Related]  

  • 5. [Metabolic syndrome and nonalcoholic fatty liver diseases in children].
    Zakharova IN; Zvenigorodskaia LA; Iablochkova SV
    Eksp Klin Gastroenterol; 2011; (11):44-8. PubMed ID: 22629718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
    Nestel PJ; Mensink RP
    Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-alcoholic fatty liver disease as an atherosclerosis risk factor].
    Roĭtberg GE; Sharkhun OO; Ushakova TI
    Eksp Klin Gastroenterol; 2010; (7):20-4. PubMed ID: 21033079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target.
    Dongiovanni P; Fracanzani AL; Fargion S; Valenti L
    J Hepatol; 2011 Oct; 55(4):920-32. PubMed ID: 21718726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease.
    Dumas ME; Kinross J; Nicholson JK
    Gastroenterology; 2014 Jan; 146(1):46-62. PubMed ID: 24211299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver and insulin resistance among petrochemical workers.
    Cotrim HP; Carvalho F; Siqueira AC; Lordelo M; Rocha R; De Freitas LA
    JAMA; 2005 Oct; 294(13):1618-20. PubMed ID: 16204660
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease and metabolic syndrome: a concise review.
    Streba LA; Cârstea D; Mitruţ P; Vere CC; Dragomir N; Streba CT
    Rom J Morphol Embryol; 2008; 49(1):13-20. PubMed ID: 18273497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: the hepatic metabolic syndrome.
    Page J
    J Am Acad Nurse Pract; 2012 Jun; 24(6):345-51. PubMed ID: 22672485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron homeostasis in the metabolic syndrome.
    Datz C; Felder TK; Niederseer D; Aigner E
    Eur J Clin Invest; 2013 Feb; 43(2):215-24. PubMed ID: 23289518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glucotoxicity, lipotoxicity and the nonalcoholic fatty liver disease].
    Zeng MD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):81-2. PubMed ID: 15727688
    [No Abstract]   [Full Text] [Related]  

  • 16. [Steatohepatitis and metabolic and nutritional abnormalities].
    Deugnier Y; Lainé F
    Gastroenterol Clin Biol; 2003 May; 27(5 Suppl):B9-12. PubMed ID: 12843931
    [No Abstract]   [Full Text] [Related]  

  • 17. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload.
    Brudevold R; Hole T; Hammerstrøm J
    PLoS One; 2008; 3(10):e3547. PubMed ID: 18958176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Padovani R; Rodella S; Zoppini G; Zenari L; Cigolini M; Falezza G; Arcaro G
    Diabetes Care; 2006 Jun; 29(6):1325-30. PubMed ID: 16732016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR).
    Vari IS; Balkau B; Kettaneh A; André P; Tichet J; Fumeron F; Caces E; Marre M; Grandchamp B; Ducimetière P;
    Diabetes Care; 2007 Jul; 30(7):1795-801. PubMed ID: 17416791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.